No enhanced GA uptake in OAT1- or OAT3-expressing cells
Cell-based study · MDCKII cells expressing human OAT1 or OAT3 compared with mock cells [1]
GA uptake was similar in transporter-expressing and mock cells under the tested plasma conditions. This negative transport result does not establish transporter inhibition or exclude uptake in other conditions.
| Endpoint | Reported result | Reference |
|---|---|---|
| Cell-associated parent GA after plasma exposure | Relative uptake comparison Similar uptake in mock, OAT1 and OAT3 cells; mean ± S.E., n = 6 for cell experiments (Fig. 10D caption). | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- 7.0 µM GA in pooled female EHBR plasma; this plasma also contained 15 µM compound 1
- Exposure duration
- 15 min at 37 °C
- Method
- Exposure to pooled plasma reconstituted at pH 5.5; comparison with mock cells
- Vehicle
- Pooled rat plasma, lyophilized and reconstituted in 10 mM MES (pH 5.5)
- Co-treatment
- Plasma mixture containing endogenous constituents and GA metabolites; not a purified GA-only treatment
- Reported limits
- n = 6 is reported without specifying independent plasma preparations. No equivalence test or transporter-inhibition endpoint is reported.
Methods and source locations
Compound reported in the paper: 18β-Glycyrrhetinic acid; Compound label in the paper: GA in pooled plasma
Applies to the reported research material; does not establish an Adooq lot, formulation equivalence or clinical efficacy.
Figure 10D and caption; corresponding Results and Methods; Chemicals and reagents
Cell-associated parent GA after plasma exposure: LC-MS/MS of cell extracts, normalized to protein; transporter function checked with p-aminohippurate and estrone sulfate probe substrates. — Figure 10D and caption; Results and Methods: Uptakes of compound 1 by rat kidney slices and cells expressing OAT1 and 3